FibroBiologics Announces Update On Its Intellectual Property Portfolio
Portfolio Extends Its Lead in Fibroblast Intellectual Property With 170 Issued Patents and 325+ Patents Issued and Pending Portfolio Covers the Therapeutic Use of Fibroblasts Across Multiple Clinical Pathways and the Manufacturing Techniques Used to Produce Them HOUSTON, Nov. 12, 2026...
Covered in this story
Call it yourself
No calls on $FBLG yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on FibroBiologics →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.